|Bid||45.05 x 800|
|Ask||46.67 x 1300|
|Day's range||44.42 - 45.92|
|52-week range||31.23 - 47.58|
|Beta (5Y monthly)||0.92|
|PE ratio (TTM)||9.08|
|Earnings date||07 Feb 2022 - 11 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Unum Group (UNM) Q4 is likely to benefit from favorable persistency trends, higher sales in the dental and vision product line and solid performance in alternative asset portfolio.
Aided by Zurich, MetLife's (MET) subsidiary completes a reinsurance deal with an aim to boost its presence in the U.K. longevity risk transfer market.
Marsh & McLennan's (MMC) fourth-quarter results are likely to reflect rate increases, and solid results of Risk and Insurance Services and Consulting segments, partly offset by higher costs.